https://pan.baidu.com/s/1mNNajavPZE5hVP6cUnERvg 学如逆水行舟,不进则退; 心似平原走马,易放难收。
Andecaliximab (GS-5745), a monoclonal antibody targeting MMP9 with high affinity and selectivity, was evaluated in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic adenocarcinoma. Patients and methods: This phase I study was completed in two parts: part A was a...
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyMatrix metalloproteinase-9 (MMP9) is implicated in pro-tumorigenic processes. Andecaliximab... MA Shah,A Starodub,S Sharma,... - 《Clinical Cancer...
Mean free plasma MMP9 levels in the GS-5745 cohort were reduced by 90% from 126.1 ng/mL at Baseline to 13.2 ng/mL (2.18) at Day 43; compared to a 17% increase from 76 ng/mL at Baseline to 89 ng/mL at Day 43 in the PBO cohort. DAS 28-CRP low disease activity or remission ...